Soleno Therapeutics Inc (NASDAQ:SLNO) saw an upside of 393.45% to $21.86 after adding $17.43 on Tuesday. The 5-day average trading volume is 4,726,309 shares of the company’s common stock. It has gained $25.00 in the past week and touched a new high 3 times within the past 5 days. An average of 1,258,677 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 530,035.
SLNO’s 1-month performance is 333.73% or $16.58 on its low of $3.69 reached on 09/07/23. The company’s shares have touched a 52-week low of $0.85 and high of $6.20, with the stock’s rally to the 52-week high happening on 09/26/23. YTD, SLNO has achieved 1004.04% or $19.64 and has reached a new high 19 times. However, the current price is up 252.58% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
SLNO stock investors last saw insider trading activity on Jun 06.SCHULER JACK W (10% Owner) most recently sold 10,000 shares at $0.91 per share on Dec 09. This transaction cost the insider $9,100. 10% Owner, SCHULER JACK W, sold 10,000 shares at a price of $0.93 on Dec 08. Then, on Dec 07, 10% Owner SCHULER JACK W sold 10,000 shares at a price of $0.96 per share. This transaction amounted to $9,600.
Valuation Metrics
SLNO stock has a beta of 0.17. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 16.08.
Soleno Therapeutics Inc’s quick ratio for the period ended June 29 was 2.33, with the current ratio over the same period at 2.33. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.02, while the total debt to equity was 0.04. The firm’s gross profit as reported stood at $0.33 million against revenue of $24.4 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income grew 20.64% to -$8.48 million, while revenue of -$8.36 million was 1.42% off the previous quarter. Analysts expected SLNO to announce -$0.83 per share in earnings in its latest quarter, but it posted -$0.81, representing a 2.40% surprise. SLNO stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 18.52 million, with total debt at $0.48 million. Shareholders hold equity totaling $9.99 million.
Let’s look briefly at Soleno Therapeutics Inc (SLNO) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 25 September was 95.63% to suggest the stock is trending Overbought, with historical volatility in this time period at 776.90%.
The stock’s 5-day moving average is $7.71, reflecting a +379.35% or $17.11 change from its current price. SLNO is currently trading +304.09% above its 20-day SMA, +503.88% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +306.37% and SMA200 by+2,158.08%.
Stochastic %K and %D was 59.71% and 45.03% and the average true range (ATR) pointed at 2.71. The RSI (14) points at 93.14%, while the 14-day stochastic is at 84.13% with the period’s ATR at 1.88. The stock’s 9-day MACD Oscillator is pointing at 3.78 and 4.63 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Soleno Therapeutics Inc (NASDAQ: SLNO), Guggenheim launched coverage with a Buy rating. Analysts offering their rating for SLNO stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate SLNO as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 3 have offered a “buy” rating.
What is SLNO’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $10.00 and a high of $19.00, with their median price target at $14.00. Looking at these predictions, the average price target given by analysts is for Soleno Therapeutics Inc (SLNO) stock is $14.33.
